Zimmer Biomet Holdings Stock Cash And Equivalents
ZBH Stock | USD 110.64 0.32 0.29% |
Zimmer Biomet Holdings fundamentals help investors to digest information that contributes to Zimmer Biomet's financial success or failures. It also enables traders to predict the movement of Zimmer Stock. The fundamental analysis module provides a way to measure Zimmer Biomet's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zimmer Biomet stock.
Last Reported | Projected for Next Year | ||
Cash And Equivalents | 338.1 M | 454.3 M |
Zimmer | Cash And Equivalents |
Zimmer Biomet Holdings Company Cash And Equivalents Analysis
Zimmer Biomet's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Zimmer Biomet Cash And Equivalents | 375.7 M |
Most of Zimmer Biomet's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zimmer Biomet Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zimmer Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Zimmer Biomet is extremely important. It helps to project a fair market value of Zimmer Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Zimmer Biomet's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zimmer Biomet's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zimmer Biomet's interrelated accounts and indicators.
Click cells to compare fundamentals
Zimmer Cash And Equivalents Historical Pattern
Today, most investors in Zimmer Biomet Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zimmer Biomet's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash and equivalents growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Zimmer Biomet cash and equivalents as a starting point in their analysis.
Zimmer Biomet Cash And Equivalents |
Timeline |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, Zimmer Biomet Holdings has 375.7 M in Cash And Equivalents. This is 54.23% lower than that of the Health Care Equipment & Supplies sector and 32.67% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 86.1% higher than that of the company.
Zimmer Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zimmer Biomet's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zimmer Biomet could also be used in its relative valuation, which is a method of valuing Zimmer Biomet by comparing valuation metrics of similar companies.Zimmer Biomet is currently under evaluation in cash and equivalents category among its peers.
Zimmer Biomet ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zimmer Biomet's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zimmer Biomet's managers, analysts, and investors.Environmental | Governance | Social |
Zimmer Fundamentals
Return On Equity | 0.0871 | ||||
Return On Asset | 0.0461 | ||||
Profit Margin | 0.14 % | ||||
Operating Margin | 0.18 % | ||||
Current Valuation | 28.09 B | ||||
Shares Outstanding | 199.07 M | ||||
Shares Owned By Insiders | 0.14 % | ||||
Shares Owned By Institutions | 93.43 % | ||||
Number Of Shares Shorted | 6.69 M | ||||
Price To Earning | 77.41 X | ||||
Price To Book | 1.78 X | ||||
Price To Sales | 2.91 X | ||||
Revenue | 7.39 B | ||||
Gross Profit | 4.92 B | ||||
EBITDA | 2.21 B | ||||
Net Income | 1.02 B | ||||
Cash And Equivalents | 375.7 M | ||||
Cash Per Share | 2.71 X | ||||
Total Debt | 6 B | ||||
Debt To Equity | 0.48 % | ||||
Current Ratio | 1.98 X | ||||
Book Value Per Share | 62.00 X | ||||
Cash Flow From Operations | 1.58 B | ||||
Short Ratio | 4.70 X | ||||
Earnings Per Share | 5.24 X | ||||
Price To Earnings To Growth | 1.45 X | ||||
Target Price | 124.92 | ||||
Number Of Employees | 18 K | ||||
Beta | 1.02 | ||||
Market Capitalization | 22.09 B | ||||
Total Asset | 21.5 B | ||||
Retained Earnings | 10.38 B | ||||
Working Capital | 1.75 B | ||||
Current Asset | 5.85 B | ||||
Current Liabilities | 1.62 B | ||||
Annual Yield | 0.01 % | ||||
Five Year Return | 0.75 % | ||||
Net Asset | 21.5 B | ||||
Last Dividend Paid | 0.96 |
About Zimmer Biomet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zimmer Biomet Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zimmer Biomet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zimmer Biomet Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Zimmer Biomet Piotroski F Score and Zimmer Biomet Altman Z Score analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.597 | Dividend Share 0.96 | Earnings Share 5.24 | Revenue Per Share 37.006 | Quarterly Revenue Growth 0.04 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.